Bronchogenic cancer, metastases, and aging
WB ERSHLER, MA SOCINSKI… - Journal of the American …, 1983 - Wiley Online Library
WB ERSHLER, MA SOCINSKI, CJ GREENE
Journal of the American Geriatrics Society, 1983•Wiley Online LibraryPreviously reported large autopsy series have indicated that elderly patients who die of
cancer are less likely to have metastatic disease than their younger counterparts. This
observation could be explained if survival were shorter in the elderly population and patients
died with smaller tumor burdens. The authors analyzed Medical Center Hospital of Vermont
(MCHV) Tumor Registry data on primary lung cancer with respect to age. As in the reported
autopsy series, at the time of diagnosis elderly patients were less likely to have metastatic …
cancer are less likely to have metastatic disease than their younger counterparts. This
observation could be explained if survival were shorter in the elderly population and patients
died with smaller tumor burdens. The authors analyzed Medical Center Hospital of Vermont
(MCHV) Tumor Registry data on primary lung cancer with respect to age. As in the reported
autopsy series, at the time of diagnosis elderly patients were less likely to have metastatic …
Previously reported large autopsy series have indicated that elderly patients who die of cancer are less likely to have metastatic disease than their younger counterparts. This observation could be explained if survival were shorter in the elderly population and patients died with smaller tumor burdens. The authors analyzed Medical Center Hospital of Vermont (MCHV) Tumor Registry data on primary lung cancer with respect to age. As in the reported autopsy series, at the time of diagnosis elderly patients were less likely to have metastatic disease. Further analysis was undertaken of the patients from this series who died and were autopsied at MCHV. Although the total numbers were small, survival was not shorter in the advanced age groups. The authors suggest that elderly patients have slower tumor growth and less metastatic disease, not because of earlier diagnosis and shorter survival, but because of senescent host factors that impede aggressive tumor growth and spread.
